Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.

doi:10.1371/journal.pone.0262770

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.

PloS one - 1 Jan 2022

Heitz Florian, Lakis Sotirios, Harter Philipp, Heikaus Sebastian, Sehouli Jalid, Talwar Jatin, Menon Roopika, Ataseven Beyhan, Bertrand Miriam, Schneider Stephanie, Mariotti Erika, Bommert Mareike, Müller Judith N, Prader Sonia, Leenders Frauke, Hengsbach Alexandra, Gloeckner Christian, Braicu Elena Ioana, Heukamp Lukas C, du Bois Andreas, Heuckmann Johannes M

Abstract excerpt

BACKGROUND: The present prospective study aimed at determining the impact of cell-free tumor DNA (ct-DNA), CA125 and HE4 from blood and ascites for quantification of tumor burden in patients with advanced high-grade serous epithelial ovarian cancer (EOC). METHODS: Genomic DNA was extracted from tumor FFPE and ct-DNA from plasma before surgery and on subsequent post-surgical days. Extracted DNA was subjected to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ascites

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CA-125 Antigen

Share to Carcinoma, Ovarian Epithelial

Share to Cell-Free Nucleic Acids

Share to Circulating Tumor DNA

Share to Cystadenocarcinoma, Serous

Share to Neoplasm Grading

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 35130283
DOI: 10.1371/journal.pone.0262770
PMCID: PMC8820624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.PMID 35130283Read ↗

Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysisSemantic proximity Read ↗

Plasma cell‐free DNA in ovarian cancerSemantic proximity Read ↗

Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.Semantic proximity Read ↗

Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.Semantic proximity Read ↗

Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancerSemantic proximity Read ↗

Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.Semantic proximity Read ↗

Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian CancerSemantic proximity Read ↗

Improving earlier non-invasive diagnosis of high-grade serous ovarian cancerSemantic proximity Read ↗

Combining circulating tumor cell and circulating cell free DNA analyses enhances liquid biopsy sensitivity in detecting high grade serous tubo-ovarian carcinomaSemantic proximity Read ↗

Concordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA: A Pilot Study.Semantic proximity Read ↗

Liquid biopsy for diagnosing epithelial ovarian cancer: quantification of cell-free DNA and p53 mutational analysis.Semantic proximity Read ↗

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.